Olema Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 13, 2025, discussing its breast cancer therapies.
Quiver AI Summary
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, announced that its President and CEO, Sean P. Bohen, M.D., Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation will be available via a live webcast on Olema's Investor Relations website, along with a recording later. Olema is working to improve outcomes for breast cancer patients with a pipeline that includes its lead product candidate, palazestrant (OP-1250), currently in two Phase 3 trials, and another candidate, OP-3136, a KAT6 inhibitor in Phase 1 studies. The company is headquartered in San Francisco and also has operations in Cambridge, Massachusetts.
Potential Positives
- Olema Pharmaceuticals is participating in a prestigious event, the 44th Annual J.P. Morgan Healthcare Conference, which can enhance its visibility and credibility in the industry.
- The presentation by the CEO could attract potential investors and partners, showcasing the company's commitment to advancing cancer treatments.
- The announcement highlights Olema's focus on innovative therapies for breast cancer, which positions it as a leader in a critical and expanding market.
- Olema is advancing multiple clinical trials, indicating a robust pipeline and the potential for future growth and development within the biopharmaceutical sector.
Potential Negatives
- None
FAQ
When is Olema Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?
Olema Pharmaceuticals will present on Tuesday, January 13, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
Where can I watch Olema's presentation live?
The live webcast of the presentation will be available on Olema's Investor Relations website at ir.olema.com.
What is the focus of Olema Pharmaceuticals?
Olema Pharmaceuticals focuses on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond.
What are Olema's lead product candidates?
Olema's lead candidates include palazestrant (OP-1250), and OP-3136, a potent KAT6 inhibitor currently in clinical trials.
Where is Olema Pharmaceuticals headquartered?
Olema Pharmaceuticals is headquartered in San Francisco, with additional operations in Cambridge, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OLMA Insider Trading Activity
$OLMA insiders have traded $OLMA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $OLMA stock by insiders over the last 6 months:
- IAN T CLARK has made 0 purchases and 3 sales selling 264,800 shares for an estimated $7,873,109.
- NASEEM ZOJWALLA (Chief Medical Officer) has made 0 purchases and 4 sales selling 269,509 shares for an estimated $7,530,147.
- DAVID C. MYLES (CH. DISCOV. & NON-CLIN DEV OFF) has made 0 purchases and 3 sales selling 51,000 shares for an estimated $1,553,543.
- CYRUS HARMON has made 0 purchases and 5 sales selling 27,881 shares for an estimated $287,035.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OLMA Hedge Fund Activity
We have seen 59 institutional investors add shares of $OLMA stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MPM BIOIMPACT LLC removed 2,378,762 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,288,079
- WOODLINE PARTNERS LP removed 1,288,000 shares (-36.7%) from their portfolio in Q3 2025, for an estimated $12,609,519
- MILLENNIUM MANAGEMENT LLC removed 939,636 shares (-73.9%) from their portfolio in Q3 2025, for an estimated $9,199,036
- SILVERARC CAPITAL MANAGEMENT, LLC added 933,541 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,139,366
- KINGDON CAPITAL MANAGEMENT, L.L.C. added 854,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,360,659
- BALYASNY ASSET MANAGEMENT L.P. added 693,179 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,786,222
- SOLEUS CAPITAL MANAGEMENT, L.P. added 619,874 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,068,566
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OLMA Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 12/12/2025
- Goldman Sachs issued a "Buy" rating on 11/21/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/18/2025
- Oppenheimer issued a "Outperform" rating on 11/18/2025
- JP Morgan issued a "Overweight" rating on 11/18/2025
- Guggenheim issued a "Buy" rating on 10/08/2025
To track analyst ratings and price targets for $OLMA, check out Quiver Quantitative's $OLMA forecast page.
$OLMA Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 6 analysts offer price targets for $OLMA in the last 6 months, with a median target of $41.5.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $60.0 on 12/12/2025
- Matthew Biegler from Oppenheimer set a target price of $48.0 on 12/11/2025
- Richard Law from Goldman Sachs set a target price of $38.0 on 12/11/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $45.0 on 12/11/2025
- Anupam Rama from JP Morgan set a target price of $32.0 on 11/18/2025
- Brad Canino from Guggenheim set a target price of $20.0 on 10/08/2025
Full Release
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast of the presentation and any accompanying materials will be available in the Events and Presentations section of Olema’s Investor Relations website at ir.olema.com . A recording of the presentation will be made available in the same location.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit
www.olema.com
.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]
